R&D Spotlight focusing on pipeline advances | 30-Oct-2024 | 07:00 | RNS |
Block Listing Six Monthly Return | 28-Oct-2024 | 07:00 | RNS |
Avacta Reports Pipeline Avances at EORTC | 24-Oct-2024 | 07:00 | RNS |
Issue of Equity and Total Voting Rights | 21-Oct-2024 | 16:00 | RNS |
Avacta and Tempus Enter Strategic Collaboration | 21-Oct-2024 | 07:00 | RNS |
Avacta Expands its Pipeline | 17-Oct-2024 | 07:00 | RNS |
Avacta appoints Chief Scientific Officer | 15-Oct-2024 | 07:00 | RNS |
Avacta Unveils Pipeline Expansion at EORTC 2024 | 10-Oct-2024 | 07:00 | RNS |
Interim Results | 30-Sep-2024 | 07:00 | RNS |
Avacta Reported Updated Phase 1 Data of AVA6000 | 16-Sep-2024 | 07:00 | RNS |
Notice of Results | 12-Sep-2024 | 07:00 | RNS |
Avacta to present clinical data at ESMO Congress | 09-Sep-2024 | 07:00 | RNS |
Director/PDMR Shareholdings and TVR | 02-Sep-2024 | 15:53 | RNS |
Convertible Bond Payment | 18-Jul-2024 | 07:00 | RNS |
Result of AGM | 26-Jun-2024 | 14:46 | RNS |
Currency | UK Pounds |
Share Price | 46.50p |
Change Today | 2.25p |
% Change | 5.08 % |
52 Week High | 140.00p |
52 Week Low | 39.75p |
Volume | 3,090,174 |
Shares Issued | 369.31m |
Market Cap | £171.73m |
Beta | 1.25 |
RiskGrade | 461 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
16:37 | 100,000 @ 46.61p |
16:35 | 9,401 @ 46.50p |
16:35 | 6,401 @ 46.50p |
16:35 | 2,076 @ 46.50p |
16:35 | 38 @ 46.50p |
CFO | Tony Peter Gardiner |
CEO | Christina Coughlin |
You are here: research